Home・Aandelen Lijst・Novocure Ltd

Novocure Ltd

Gesloten

SectorGezondheidszorg

17.79 -10.6

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

17.23

Max

21.33

Belangrijke statistieken
By Trading Economics
Inkomsten	-47M -71M
Verkoop	-295K 174M
EPS	-0.62
Winstmarge	-40.871
Werknemers	1,605
EBITDA	-29M -63M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+27.56% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	401M 1.8B
Vorige openingsprijs	28.39
Vorige sluitingsprijs	17.79

Nieuwssentiment

By Acuity

55%

45%

273 / 340 Rangschikking in Healthcare

Novocure Ltd Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 jul 2026, 19:41 UTC

News

Social Media

Novocure Ltd's stock is lower following its Q2 earnings report, despite a narrower loss and revenue beat. Analysts lowered price targets amid ongoing investor concerns.

22 jul 2026, 20:04 UTC

Shares of Novocure Ltd. are lower today, continuing a decline since Tuesday's close amid broader market uncertainty ahead of the Federal Reserve meeting.

20 jul 2026, 14:36 UTC

Novocure Ltd. is trading higher since Friday's close, despite pulling back from an early session high amid broader market volatility from geopolitical tensions.

Peer Vergelijking

Prijswijziging

Novocure Ltd Prognose

Koersdoel

By TipRanks

27.56% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 25.5 USD 27.56%

Hoogste 52 USD

Laagste 17 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Novocure Ltd - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Novocure Ltd - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

273 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.